Open AccessThe role of artificial intelligence in assessing the progression of fibrosing lung diseases
Author(s) -
А. А. Speranskaya
Publication year - 2022
Publication title -
terapevtičeskij arhiv
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.181
H-Index - 14
eISSN - 2309-5342
pISSN - 0040-3660
DOI - 10.26442/00403660.2022.03.201407
Subject(s) - medicine , interstitial lung disease , lung , pneumonia , interstitial pneumonia , covid-19 , retrospective cohort study , usual interstitial pneumonia , hypersensitivity pneumonitis , pathology , idiopathic pulmonary fibrosis , lung volumes , disease , radiology , infectious disease (medical specialty)
. The widespread use of artificial intelligence (AI) programs during the COVID-19 pandemic to assess the exact volume of lung tissue damage has allowed them to train a large number of radiologists. The simplicity of the program for determining the volume of the affected lung tissue in acute interstitial pneumonia, which has density indicators in the range from -200 HU to -730 HU, which includes the density indicators of "ground glass" and reticulation (the main radiation patterns in COVID-19) allows you to accurately determine the degree of prevalence process. The characteristics of chronic interstitial pneumonia, which are progressive in nature, fit into the same density framework.
Аim. To аssess AI's ability to assess the progression of fibrosing lung disease using lung volume counting programs used for COVID-19 and chronic obstructive pulmonary disease.
Results. Retrospective analysis of computed tomography data during follow-up of 75 patients with progressive fibrosing lung disease made it possible to assess the prevalence and growth of interstitial lesions.
Conclusion. Using the experience of using AI programs to assess acute interstitial pneumonia in COVID-19 can be applied to chronic interstitial pneumonia.